GAM Holding’s Ultragenyx Pharmaceutical RARE Stock Holding History

GAM Holding’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50,700	Closed	-$3.9M	–	948
2018 Q2	$3.9M	Buy	50,700 +1,000	+2%	+$64.6K	0.14%	179
2018 Q1	$2.53M	Sell	49,700 -28,400	-36%	-$1.43M	0.09%	242
2017 Q4	$3.62M	Hold	78,100	–	–	0.11%	224
2017 Q3	$4.16M	Hold	78,100	–	–	0.18%	161
2017 Q2	$4.85M	Hold	78,100	–	–	0.07%	334
2017 Q1	$5.29M	Buy	78,100 +11,700	+18%	+$892K	0.08%	283
2016 Q4	$4.67M	Sell	66,400 -7,900	-11%	-$560K	0.08%	276
2016 Q3	$5.27M	Sell	74,300 -1,500	-2%	-$95.7K	0.09%	249
2016 Q2	$3.71M	Buy	75,800 +37,900	+100%	+$2.45M	0.06%	363
2016 Q1	$2.4M	Buy	37,900 +5,400	+17%	+$353K	0.04%	433
2015 Q4	$3.65M	Buy	32,500 +11,300	+53%	+$1.13M	0.06%	348
2015 Q3	$2.04M	Buy	+21,200	New	+$2.43M	0.04%	481

Other funds holding RARE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

GAM Holding's RARE Position: Q3 2018 in Review

GAM Holding sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2018, closing a stake of 50,700 shares — an estimated $3.9M sold.

GAM Holding first reported a position in RARE in Q3 2015 and held it in 12 quarters. The position peaked at $5.29M in Q1 2017. 176 funds tracked by Wall St. Rank hold RARE as of Q3 2018.

GAM Holding reported no remaining Ultragenyx Pharmaceutical position as of Q3 2018 after selling out during the quarter.
GAM Holding sold 50,700 Ultragenyx Pharmaceutical shares in Q3 2018, an estimated $3.9M.
GAM Holding first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 12 quarters.
GAM Holding's Ultragenyx Pharmaceutical position peaked at $5.29M in Q1 2017.
176 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2018.

Based on GAM Holding's 13F filing for Q3 2018, filed 13 Nov 2018.